Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment.

MLA

Larsen, Sarah L., et al. “Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment.” PLoS ONE, vol. 10, no. 2, Feb. 2015, pp. 1–19. EBSCOhost, https://doi.org/10.1371/journal.pone.0118346.

APA

Larsen, S. L., Laenkholm, A.-V., Duun-Henriksen, A. K., Bak, M., Lykkesfeldt, A. E., & Kirkegaard, T. (2015). Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment. PLoS ONE, 10(2), 1–19. https://doi.org/10.1371/journal.pone.0118346

Chicago

Larsen, Sarah L., Anne-Vibeke Laenkholm, Anne Katrine Duun-Henriksen, Martin Bak, Anne E. Lykkesfeldt, and Tove Kirkegaard. 2015. “Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment.” PLoS ONE 10 (2): 1–19. doi:10.1371/journal.pone.0118346.